Dianthus Therapeutics, Inc.'s DNTH103 is being evaluated in the phase 2 MaGic trial, which is targeting patients with generalized myasthenia gravis. The global myasthenia gravis treatment market size ...
The study is the first to identify a damage response pathway that is distinct from but parallel to the classical pathway triggered by pathogens. It's a dangerous world out there. From bacteria and ...
Share on Pinterest A study offers new clues on why long COVID persists in some individuals. krisanapong detraphiphat/Getty Images Despite the debilitating nature of long COVID, there is an absence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback